Patient satisfaction with tildrakizumab treatment in a Phase 4 real-world study of tildrakizumab in patients with moderate-to-severe psoriasis

被引：0
|
作者：
Bhatia, Neal [1 ]
Vasquez, J. Gabriel [2 ]
Schenkel, Brad [3 ]
Rozzo, Stephen J. [3 ]
Heim, Jayme [2 ]
机构：
[1] Therapeut Clin Res, San Diego, CA USA
[2] West Michigan Dermatol, Grandville, MI USA
[3] Sun Pharmaceut Ind Inc, Princeton, NJ USA
来源：
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2023年 / 89卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
42281
引用
收藏
页码：AB72 / AB72
页数：1
相关论文
共 50 条
  • [1] Safety of tildrakizumab in a Phase 4 real-world study in patients with moderate-to-severe plaque psoriasis
    Vasquez, J. Gabriel
    Bhatia, Neal
    Schenkel, Brad
    Rozzo, Stephen J.
    Heim, Jayme
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : AB85 - AB85
  • [2] REAL-WORLD EFFECTIVENESS AND SAFETY IN A PHASE 4 STUDY OF TILDRAKIZUMAB IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS
    Bhatia, N.
    Vasquez, J. G.
    Schenkel, B.
    Rozzo, S. J.
    Heim, J.
    VALUE IN HEALTH, 2023, 26 (06) : S57 - S57
  • [3] Patients' quality of life in a Phase 4 real-world study of tildrakizumab in moderate-to-severe plaque psoriasis
    Heim, Jayme
    Vasquez, J. Gabriel
    Rozzo, Stephen J.
    Schenkel, Brad
    Bhatia, Neal
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : AB204 - AB204
  • [4] Real-World Effectiveness of Tildrakizumab for Moderate-to-Severe Plaque Psoriasis in Canada
    Abu-Hilal, Mohannad
    Cowger, Jeff
    Bawazir, Mohammed
    Sajic, Dusan
    Savinova, Iryna
    Yap, Belinda
    El-Sayegh, Rami
    Bolatova, Talshyn
    Chan, Pak
    Cy, Ajith
    JOURNAL OF CUTANEOUS MEDICINE AND SURGERY, 2024,
  • [5] Real-world effectiveness of tildrakizumab in a Phase 4 study in patients with moderate-to- severe plaque psoriasis
    Bhatia, Neal
    Vasquez, J. Gabriel
    Schenkel, Brad
    Rozzo, Stephen J.
    Heim, Jayme
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : AB216 - AB216
  • [6] Tildrakizumab for the treatment of moderate-to-severe psoriasis: a 52-week, real-world Portuguese multicentric study
    Torres, Tiago
    Varela, Paulo
    Bastos, Pedro Mendes
    Magina, Sofia
    Henrique, Martinha
    Ferreira, Paulo
    DRUGS IN CONTEXT, 2024, 13
  • [7] QUALITY OF LIFE AND TREATMENT SATISFACTION WITH TILDRAKIZUMAB IN MODERATE-TO-SEVERE PSORIASIS PATIENTS: 52-WEEK INTERIM DATA OF THE REAL-WORLD POSITIVE STUDY
    Augustin, Matthias
    Sommer, Raquel
    Reguiai, Ziad
    Gerdes, Sascha
    Dauden, Esteban
    Weger, Wolfgang
    Maul, Julia-Tatjana
    Laws, Philip
    Naldi, Luigi
    Ghislain, Pierre-Dominique
    de Jong, Elke
    Mburu, Sicily
    Koscielny, Volker
    Massana, Eric
    Kasujee, Ismail
    Mrowietz, Ulrich
    ACTA DERMATO-VENEREOLOGICA, 2024, 104
  • [8] A phase 4, real-world study of tildrakizumab in moderate to severe psoriasis: Week 28 interim analysis
    Heim, Jayme
    Vasquez, J. Gabriel
    Beute, Paulita
    Torres, Monique
    Rozzo, Stephen J.
    Bhatia, Neal
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (03) : AB132 - AB132
  • [9] A Phase 4, real-world study of tildrakizumab in moderate to severe psoriasis: Week 28 interim analysis
    Heim, Jayme
    Vasquez, J. Gabriel
    Beute, Paulita
    Torres, Monique
    Rozzo, Stephen J.
    Bhatia, Neal
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2022, 63 : 6 - 6
  • [10] Improvements in Psoriasis-Related Work Productivity with Tildrakizumab: Results from a Phase 4 Real-World Study in Patients with Moderate-to-Severe Plaque Psoriasis
    Tina Bhutani
    John Koo
    Jayme Heim
    Neal Bhatia
    Jacob Mathew
    Thomas Ferro
    J. Gabriel Vasquez
    Dermatology and Therapy, 2024, 14 : 1019 - 1025
12345